Open AccessiPSC technology‐based regenerative therapy for diabetes
Author(s) -
Kondo Yasushi,
Toyoda Taro,
Inagaki Nobuya,
Osafune Kenji
Publication year - 2018
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12702
Subject(s) - induced pluripotent stem cell , embryonic stem cell , medicine , regenerative medicine , progenitor cell , diabetes mellitus , stem cell , transplantation , pancreas , cell therapy , bioinformatics , immune system , cancer research , immunology , microbiology and biotechnology , biology , endocrinology , genetics , gene
The directed differentiation of human pluripotent stem cells, such as embryonic stem cells ( hESC s) and induced pluripotent stem cells (hi PSC s), into pancreatic endocrine lineages has been vigorously examined by reproducing the in vivo developmental processes of the pancreas. Recent advances in this research field have enabled the generation from hESC s/ iPSC s of functionally mature β‐like cells in vitro that show glucose‐responsive insulin secretion ability. The therapeutic potentials of hESC / iPSC ‐derived pancreatic cells have been evaluated using diabetic animal models, and transplantation methods including immunoprotective devices that prevent immune responses from hosts to the implanted pancreatic cells have been investigated towards the development of regenerative therapies against diabetes. These efforts led to the start of a clinical trial that involves the implantation of hESC ‐derived pancreatic progenitors into type 1 diabetes patients. In addition, patient‐derived iPSC s have been generated from diabetes‐related disorders towards the creation of novel in vitro disease models and drug discovery, although few reports so far have analyzed the disease mechanisms. Considering recent advances in differentiation methods that generate pancreatic endocrine lineages, we will see the development of novel cell therapies and therapeutic drugs against diabetes based on iPSC technology‐based research in the next decade.